Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
♫ Tuesday, May 9th, 2023-- Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 ---- Full Six-Month Safety Data from Both Adult Studies Demonstrated VAX-24 Safety and Tolerability Results Similar to PCV20 at All Doses Studied --
Follow this link:
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update